Metformin Use Likely Reduces Alzheimer's Disease Risk
Investigating the causal effect of the drug's potential risk reduction.
Stay updated with breaking news from Mci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigating the causal effect of the drug's potential risk reduction.
A biomarker typically linked with Alzheimer's disease may also signal amyotrophic lateral sclerosis.
Lecanemab can reduce amyloid plaques within the first months after treatment initiation and is linked to improved clinical signs in as early as 6 months, updates from a phase 2 trial show.
Study involved neurocognitive evaluation and compared data to age-matched healthy controls.
A meta-analysis finds an association between shift work and cognitive impairments that may increase the risk of injuries and mistakes in the workplace.